Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Editorial

  • Editorial
    Cancer Immunology Research: A One-Year Anniversary
    Glenn Dranoff
    Cancer Immunol Res July 1 2014 2 (7) 591-591; DOI:10.1158/2326-6066.CIR-14-0097

Masters of Immunology

  • Masters of Immunology
    The Thymus in Immunity and in Malignancy
    Harald von Boehmer
    Cancer Immunol Res July 1 2014 2 (7) 592-597; DOI:10.1158/2326-6066.CIR-14-0070

Cancer Immunology at the Crossroads: Experimental Immunotherapies

  • Cancer Immunology at the Crossroads: Experimental Immunotherapies
    Hostile, Hypoxia–A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
    Michail V. Sitkovsky, Stephen Hatfield, Robert Abbott, Bryan Belikoff, Dmitriy Lukashev and Akio Ohta
    Cancer Immunol Res July 1 2014 2 (7) 598-605; DOI:10.1158/2326-6066.CIR-14-0075

Milestones in Cancer Immunology

  • Milestones in Cancer Immunology
    The Second Annual AACR–Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
    Cancer Immunol Res July 1 2014 2 (7) 606-609; DOI:10.1158/2326-6066.CIR-14-0094

Priority Brief

  • Priority Brief
    A Soluble Form of CD80 Enhances Antitumor Immunity by Neutralizing Programmed Death Ligand-1 and Simultaneously Providing Costimulation
    Samuel T. Haile, Lucas A. Horn and Suzanne Ostrand-Rosenberg
    Cancer Immunol Res July 1 2014 2 (7) 610-615; DOI:10.1158/2326-6066.CIR-13-0204

    Haile and colleagues report that CD80-Fc effectively maintained PD-1+ T-cell activation and IFNγ production by blocking PD-L1-mediated immune suppression and costimulating CD28, and suggest the development of CD80-Fc as a therapeutic agent.

Research Articles

  • Research Articles | AuthorChoice
    Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
    Eric R. Lutz, Annie A. Wu, Elaine Bigelow, Rajni Sharma, Guanglan Mo, Kevin Soares, Sara Solt, Alvin Dorman, Anthony Wamwea, Allison Yager, Daniel Laheru, Christopher L. Wolfgang, Jiang Wang, Ralph H. Hruban, Robert A. Anders, Elizabeth M. Jaffee and Lei Zheng
    Cancer Immunol Res July 1 2014 2 (7) 616-631; DOI:10.1158/2326-6066.CIR-14-0027

    Lutz and colleagues show that an allogeneic vaccine given with or without low-dose cyclophosphamide converted pancreatic cancer into an immunogenic cancer with infiltrating effector lymphocytes and formation of tertiary lymphoid aggregates that are regulatory structures of adaptive immunity.

  • Research Articles
    Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
    F. Stephen Hodi, Donald Lawrence, Cecilia Lezcano, Xinqi Wu, Jun Zhou, Tetsuro Sasada, Wanyong Zeng, Anita Giobbie-Hurder, Michael B. Atkins, Nageatte Ibrahim, Philip Friedlander, Keith T. Flaherty, George F. Murphy, Scott Rodig, Elsa F. Velazquez, Martin C. Mihm Jr, Sara Russell, Pamela J. DiPiro, Jeffrey T. Yap, Nikhil Ramaiya, Annick D. Van den Abbeele, Maria Gargano and David McDermott
    Cancer Immunol Res July 1 2014 2 (7) 632-642; DOI:10.1158/2326-6066.CIR-14-0053

    Hodi and colleagues report the safety and efficacy of targeting angiogenesis and CTLA-4 in a phase I trial of 46 patients with metastatic melanoma, which revealed the influence of VEGF-A blockade on inflammation, lymphocyte trafficking, and immune regulation, and their synergistic therapeutic effects.

  • Research Articles
    Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
    Zachary A. Cooper, Vikram R. Juneja, Peter T. Sage, Dennie T. Frederick, Adriano Piris, Devarati Mitra, Jennifer A. Lo, F. Stephen Hodi, Gordon J. Freeman, Marcus W. Bosenberg, Martin McMahon, Keith T. Flaherty, David E. Fisher, Arlene H. Sharpe and Jennifer A. Wargo
    Cancer Immunol Res July 1 2014 2 (7) 643-654; DOI:10.1158/2326-6066.CIR-13-0215

    Cooper, Juneja, Sage, and colleagues show that combining BRAF and PD-1/PD-L1 blockade slowed tumor growth and prolonged survival in a melanoma mouse model, with increased number and activity of tumor-infiltrating lymphocytes similar to that in a human melanoma patient treated with this regimen.

  • Research Articles | AuthorChoice
    The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells
    Kutlu G. Elpek, Viviana Cremasco, Hua Shen, Christopher J. Harvey, Kai W. Wucherpfennig, Daniel R. Goldstein, Paul A. Monach and Shannon J. Turley
    Cancer Immunol Res July 1 2014 2 (7) 655-667; DOI:10.1158/2326-6066.CIR-13-0209

    Elpek and colleagues analyzed the developmental and transcriptomic signatures of infiltrating myeloid cells in three mouse tumor models and report that tumor-associated macrophages and neutrophils exhibited different frequencies, gene expression profiles, and functions dependent on cancer types but not locations.

  • Research Articles
    Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
    Benjamin Weide, Thomas K. Eigentler, Annette Pflugfelder, Henning Zelba, Alexander Martens, Graham Pawelec, Leonardo Giovannoni, Pier Adelchi Ruffini, Giuliano Elia, Dario Neri, Ralf Gutzmer, Jürgen C. Becker and Claus Garbe
    Cancer Immunol Res July 1 2014 2 (7) 668-678; DOI:10.1158/2326-6066.CIR-13-0206

    Weide and colleagues show that intralesional therapy using the immunocytokine L19–IL2 elicited a high rate of clinical and systemic immune responses in patients with stage III melanoma and report their observation of favorable distant metastasis-free and overall survival in these patients after treatment.

  • Research Articles
    ERK-Dependent Downregulation of the Atypical Chemokine Receptor D6 Drives Tumor Aggressiveness in Kaposi Sarcoma
    Benedetta Savino, Nicoletta Caronni, Achille Anselmo, Fabio Pasqualini, Elena Monica Borroni, Gianluca Basso, Giuseppe Celesti, Luigi Laghi, Athanasia Tourlaki, Vinicio Boneschi, Lucia Brambilla, Manuela Nebuloni, Gianluca Vago, Alberto Mantovani, Massimo Locati and Raffaella Bonecchi
    Cancer Immunol Res July 1 2014 2 (7) 679-689; DOI:10.1158/2326-6066.CIR-13-0202

    Savino, Caronni, and colleagues report that D6 expression was inversely correlated with increased tumor-associated M2-macrophages and aggressiveness in ERK pathway–activated Kaposi sarcoma (KS), and suggest targeting of CCR2 and the ERK pathway as a therapeutic option for patients with KS.

  • Research Articles
    Programmed Cell Death Ligand 1 Expression in Osteosarcoma
    Jacson K. Shen, Gregory M. Cote, Edwin Choy, Pei Yang, David Harmon, Joseph Schwab, G. Petur Nielsen, Ivan Chebib, Soldano Ferrone, Xinhui Wang, Yangyang Wang, Henry Mankin, Francis J. Hornicek and Zhenfeng Duan
    Cancer Immunol Res July 1 2014 2 (7) 690-698; DOI:10.1158/2326-6066.CIR-13-0224

    Shen, Cote, and colleagues developed a quantitative RNA-based PD-L1 assay and report PD-L1 expression in 84% of human osteosarcomas, of which 24% were at high levels and correlated with TILs, indicating that this subset of patients may benefit from anti-PD-L1 immunotherapy.

Correction

  • Correction
    Correction: Oncolytic Viruses and Their Application to Cancer Immunotherapy
    Cancer Immunol Res July 1 2014 2 (7) 699-699; DOI:10.1158/2326-6066.CIR-14-0089

Back to top
PreviousNext
Cancer Immunology Research: 2 (7)
July 2014
Volume 2, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Jump to

  • Editorial
  • Masters of Immunology
  • Cancer Immunology at the Crossroads: Experimental Immunotherapies
  • Milestones in Cancer Immunology
  • Priority Brief
  • Research Articles
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Characterization of Murine Syngeneic Tumor Models
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement